
GLENMARKGlenmark Pharmaceuticals Ltd.
Glenmark Pharmaceuticals Q2 FY27 Results: Consolidated Net Profit ₹264 Crore on Total Income of ₹4,250 Crore
Glenmark Pharmaceuticals (NSE: GLENMARK) reported consolidated total income of ₹4,249.87 crore and consolidated net profit of ₹263.83 crore for the quarter ended 30 Sep 2026, it said in a filing on 05 Nov 2026. Standalone total income was ₹2,584.01 crore and standalone net profit was ₹434.89 crore.
- Earnings
- Pharmaceuticals